CN116535508A - 抗pd-l1抗体及其制备和使用方法 - Google Patents

抗pd-l1抗体及其制备和使用方法 Download PDF

Info

Publication number
CN116535508A
CN116535508A CN202310737246.6A CN202310737246A CN116535508A CN 116535508 A CN116535508 A CN 116535508A CN 202310737246 A CN202310737246 A CN 202310737246A CN 116535508 A CN116535508 A CN 116535508A
Authority
CN
China
Prior art keywords
antigen
amino acid
antibody
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310737246.6A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·科瓦切维奇
夏冬
安妮·詹森
乔恩·法莱
布莱尔·伦肖
杰弗里·B·阿达莫
菲尔·谭
高泽人
朱义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Bailidote Biological Pharmaceutical Co ltd, Seattle Immunization Co filed Critical Chengdu Bailidote Biological Pharmaceutical Co ltd
Publication of CN116535508A publication Critical patent/CN116535508A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202310737246.6A 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法 Pending CN116535508A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762524553P 2017-06-25 2017-06-25
US62/524,553 2017-06-25
PCT/US2018/039144 WO2019005634A2 (en) 2017-06-25 2018-06-22 ANTI-PD-L1 ANTIBODIES AND METHODS OF PREPARATION AND USE
CN201880038275.0A CN110831972B (zh) 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880038275.0A Division CN110831972B (zh) 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN116535508A true CN116535508A (zh) 2023-08-04

Family

ID=64742649

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310737246.6A Pending CN116535508A (zh) 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法
CN201880038275.0A Active CN110831972B (zh) 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880038275.0A Active CN110831972B (zh) 2017-06-25 2018-06-22 抗pd-l1抗体及其制备和使用方法

Country Status (5)

Country Link
US (1) US11560431B2 (https=)
EP (1) EP3645738A4 (https=)
JP (2) JP7383605B2 (https=)
CN (2) CN116535508A (https=)
WO (1) WO2019005634A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020098785A1 (zh) * 2018-11-16 2020-05-22 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
EP4118120A4 (en) 2020-03-12 2024-04-17 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS
BR112023016025A2 (pt) * 2021-02-10 2023-10-31 Jiangxi Jemincare Group Co Ltd Anticorpo anti-pd-l1 e uso dos mesmos
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CA2916681A1 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MX2016007885A (es) * 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
DK3221355T3 (da) * 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
EP3763827A1 (en) * 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
KR102785809B1 (ko) * 2017-11-02 2025-03-26 시스트이뮨, 인코포레이티드 이중특이성 항체 및 이의 제조 및 사용 방법
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Also Published As

Publication number Publication date
JP2024023249A (ja) 2024-02-21
JP7610680B2 (ja) 2025-01-08
US20220002417A1 (en) 2022-01-06
WO2019005634A2 (en) 2019-01-03
CN110831972A (zh) 2020-02-21
CN110831972B (zh) 2023-05-12
EP3645738A2 (en) 2020-05-06
JP2020530776A (ja) 2020-10-29
JP7383605B2 (ja) 2023-11-20
US11560431B2 (en) 2023-01-24
EP3645738A4 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7490109B2 (ja) 抗ｐｄ－１抗体とその作製及び使用方法
JP7610680B2 (ja) 抗ｐｄ－ｌ１抗体とその作製及び使用方法
JP7164596B2 (ja) 抗ｃｄ３抗体とその作製及び使用方法
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240630

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Applicant before: Seattle Immunization Co.

Country or region before: U.S.A.

Applicant before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China